Abstract:Ethnopharmacological relevance: Chronic pain management represents a serious healthcare problem worldwide. The use of opioid analgesics for pain has always been hampered by their side effects; in particular, the addictive liability associated with chronic use. Finding a morphine replacement has been a long-standing goal in the field of analgesia. In traditional Chinese medicine, processed Buthus martensii Karsch (BmK) scorpion has been used as a painkiller to treat chronic inflammatory arthritis and spondylitis, so called "Scorpio-analgesia". However, the molecular basis and the underline mechanism for the Scorpio-analgesia are still unclear. Aim of the study: The study aims to investigate the molecular basis of "Scorpio analgesia" and identify novel analgesics from BmK scorpion. Materials and methods: In this study, the analgesic abilities were determined using formalin-, acetic acid-and complete Freund's adjuvant-induced pain models. The effect of BmK venom and processed BmK venom on Nav1.7 were detected by whole-cell voltage-clamp recordings on HEK293-hNav1.7 stable cell line. Action potentials in Dorsal root ganglion (DRG) neurons induced by Makatoxin-3-R58A were recorded in current-clamp mode. The content of Makatoxin-3 was detected using competitive enzyme-linked immunosorbent assay based on the Makatoxin-3 antibody. High performance liquid chromatography, western blot and circular dichroism spectroscopy were used to analysis the stability of Makatoxin-3. Results: Here we demonstrate that Makatoxin-3, an alpha-like toxin in BmK scorpion venom targeting Nav1.7 is the critical component in Scorpio-analgesia. The analgesic effect of Makatoxin-3 could not be reversed by naloxone and is more potent than Nav1.7-selective inhibitors and non-steroidal anti-inflammatory drugs in inflammatory models. Moreover, a R58A mutant of Makatoxin-3 is capable of eliciting analgesia effect without inducing pain response. Conclusions: This study advances ion channel biology and proposes Nav1.7 agonists, rather than the presumed Nav1.7-only blockers, for non-narcotic relief of chronic pain.

A New Coumarin from Murraya Alata Activates TRPV1 Channel

Selective Activation of Nociceptor TRPV1 Channel and Reversal of Inflammatory Pain in Mice by a Novel Coumarin Derivative Muralatin L from Murraya Alata

Anti-inflammatory Coumarin and Benzocoumarin Derivatives from Murraya Alata.

Coumarin Derivatives from the Leaves and Twigs of Murraya Exotica L. and Their Anti-Inflammatory Activities

Identification of Two Natural Coumarin Enantiomers for Selective Inhibition of TRPV2 Channels

5-Demethoxy-10′-ethoxyexotimarin F, a New Coumarin with MAO-B Inhibitory Potential from Murraya exotica L.

Furanocoumarins are a novel class of modulators for the transient receptor potential vanilloid type 1 (TRPV1) channel

Uncaria Rhynchophylla and hirsuteine as TRPV1 agonists inducing channel desensitization

Coumarin and Spirocyclopentenone Derivatives from the Leaves and Stems of Murraya Paniculata (L.) Jack.

Anti-Inflammatory Prenylated Phenylpropenols and Coumarin Derivatives from Murraya Exotica.

Novel marine natural products as effective TRPV1 channel blockers

Murradiate and Murradiol, Two Structurally Unique Heterodimers of Carbazole-Monoterpene and Carbazole-Phenylethanol from Murraya Tetramera

Nitrogen Oxide Inhibitory Trimeric And Dimeric Carbazole Alkaloids From Murraya Tetramera

Discovery of novel TRPV1 modulators through machine learning‐based molecular docking and molecular similarity searching

Makatoxin-3, a Thermostable Nav1.7 Agonist from Buthus Martensii Karsch (bmk) Scorpion Elicits Non-Narcotic Analgesia in Inflammatory Pain Models.

Trimeric and Dimeric Carbazole Alkaloids from Murraya microphylla

New natural agonists of the transient receptor potential Ankyrin 1 (TRPA1) channel

Design, synthesis, and analgesia evaluation of novel Transient Receptor Potential Vanilloid 1 (TRPV1) agonists modified from Cannabidiol (CBD)

Biological Activity and Chemical Constituents of Essential Oil and Extracts of Murraya Microphylla

Novel dual-target μ‐opioid and TRPV1 ligands as potential pharmacotherapeutics for pain management

Transient receptor potential vanilloid 1 involved in the analgesic effects of total flavonoids extracted from Longxuejie ()